Russell Investments Group’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $327M | Buy |
1,506,385
+123,602
| +9% | +$27.4M | 0.35% | 37 |
|
|
2025
Q4 | $316M | Buy |
1,382,783
+35,951
| +3% | +$8.19M | 0.34% | 39 |
|
|
2025
Q3 | $311M | Buy |
1,346,832
+179,450
| +15% | +$36.5M | 0.35% | 37 |
|
|
2025
Q2 | $216M | Buy |
1,167,382
+16,700
| +1% | +$3.1M | 0.28% | 65 |
|
|
2025
Q1 | $241M | Sell |
1,150,682
-38,604
| -3% | -$7.5M | 0.33% | 46 |
|
|
2024
Q4 | $211M | Buy |
1,189,286
+38,684
| +3% | +$7.11M | 0.29% | 55 |
|
|
2024
Q3 | $227M | Buy |
1,150,602
+82,695
| +8% | +$15.4M | 0.33% | 48 |
|
|
2024
Q2 | $183M | Sell |
1,067,907
-9,084
| -0.8% | -$1.5M | 0.29% | 56 |
|
|
2024
Q1 | $196M | Buy |
1,076,991
+20,543
| +2% | +$3.54M | 0.31% | 56 |
|
|
2023
Q4 | $164M | Buy |
1,056,448
+87,370
| +9% | +$12.7M | 0.29% | 63 |
|
|
2023
Q3 | $145M | Buy |
969,078
+95,308
| +11% | +$14M | 0.29% | 61 |
|
|
2023
Q2 | $118M | Buy |
873,770
+14,146
| +2% | +$2.07M | 0.23% | 83 |
|
|
2023
Q1 | $137M | Buy |
859,624
+14,308
| +2% | +$2.19M | 0.27% | 67 |
|
|
2022
Q4 | $137M | Sell |
845,316
-73,809
| -8% | -$11.3M | 0.28% | 67 |
|
|
2022
Q3 | $124M | Buy |
919,125
+50,747
| +6% | +$7.28M | 0.27% | 65 |
|
|
2022
Q2 | $133M | Buy |
868,378
+15,837
| +2% | +$2.42M | 0.27% | 65 |
|
|
2022
Q1 | $138M | Sell |
852,541
-185,399
| -18% | -$26.9M | 0.24% | 77 |
|
|
2021
Q4 | $141M | Sell |
1,037,940
-58,811
| -5% | -$6.95M | 0.22% | 82 |
|
|
2021
Q3 | $118M | Sell |
1,096,751
-87,359
| -7% | -$9.98M | 0.2% | 101 |
|
|
2021
Q2 | $133M | Sell |
1,184,110
-227,160
| -16% | -$25.6M | 0.22% | 79 |
|
|
2021
Q1 | $153M | Sell |
1,411,270
-130,656
| -8% | -$14M | 0.27% | 52 |
|
|
2020
Q4 | $165M | Sell |
1,541,926
-301,816
| -16% | -$29M | 0.33% | 45 |
|
|
2020
Q3 | $161M | Sell |
1,843,742
-103,355
| -5% | -$9.73M | 0.35% | 34 |
|
|
2020
Q2 | $191M | Sell |
1,947,097
-619,469
| -24% | -$54.5M | 0.42% | 31 |
|
|
2020
Q1 | $195M | Buy |
2,566,566
+127,544
| +5% | +$10.9M | 0.51% | 25 |
|
|
2019
Q4 | $216M | Buy |
2,439,022
+148,690
| +6% | +$12.3M | 0.4% | 32 |
|
|
2019
Q3 | $173M | Buy |
2,290,332
+913,015
| +66% | +$62.6M | 0.34% | 42 |
|
|
2019
Q2 | $99.2M | Buy |
1,377,317
+691,365
| +101% | +$54.3M | 0.19% | 113 |
|
|
2019
Q1 | $55.1M | Buy |
685,952
+155,134
| +29% | +$12.7M | 0.1% | 228 |
|
|
2018
Q4 | $48.8M | Sell |
530,818
-337,425
| -39% | -$29.7M | 0.11% | 207 |
|
|
2018
Q3 | $82.1M | Buy |
868,243
+173,222
| +25% | +$16.4M | 0.16% | 133 |
|
|
2018
Q2 | $64.4M | Sell |
695,021
-138,022
| -17% | -$13.5M | 0.13% | 151 |
|
|
2018
Q1 | $78.5M | Buy |
833,043
+299,025
| +56% | +$32.8M | 0.13% | 168 |
|
|
2017
Q4 | $52.2M | Sell |
534,018
-30,556
| -5% | -$2.88M | 0.09% | 270 |
|
|
2017
Q3 | $50.2M | Buy |
564,574
+227,148
| +67% | +$17.3M | 0.09% | 281 |
|
|
2017
Q2 | $24.5M | Sell |
337,426
-115,588
| -26% | -$7.77M | 0.04% | 511 |
|
|
2017
Q1 | $29.5M | Buy |
453,014
+26,086
| +6% | +$1.64M | 0.05% | 423 |
|
|
2016
Q4 | $26.8M | Buy |
+426,928
| New | +$26.1M | 0.05% | 442 |
|
Other funds holding ABBV
VCM
VPM
Russell Investments Group's ABBV Position: Q1 2026 in Review
Russell Investments Group increased its AbbVie (ABBV) stake by 8.9% in Q1 2026, buying an estimated $27.4M and bringing the position to 1,506,385 shares worth $327M. The position accounts for 0.35% of the portfolio, ranked #37.
Russell Investments Group first reported a position in ABBV in Q4 2016 and has held it in 38 quarters since. 4,079 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Russell Investments Group held 1,506,385 shares of AbbVie worth $327M as of Q1 2026.
- Russell Investments Group bought 123,602 AbbVie shares in Q1 2026, an estimated $27.4M.
- AbbVie made up 0.35% of Russell Investments Group's portfolio in Q1 2026, its #37 holding.
- Russell Investments Group first reported a position in AbbVie in Q4 2016 and has held it in 38 quarters since.
- 4,079 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.